文献速递前列腺癌

立体定向放疗治疗前列腺切除术后前列腺床复发:多中心系列研究

Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series.
PubMed 文献 · BJU Int · 2019-11-15

该多中心回顾性研究评估了立体定向挽救性放疗(SSRT)对未接受过放疗的肉眼可见前列腺床复发患者的安全性和有效性。90例患者接受30-40 Gy/5次SSRT,平均随访21.2个月,完全生化反应率43.3%,无>2级毒性。SSRT可获得显著生化控制并延迟ADT。

要点

  • SSRT(30-40 Gy/5次)对前列腺床肉眼复发安全,无>2级毒性。
  • 完全生化反应(PSA nadir<0.2 ng/mL)率为43.3%。
  • BCRFS1中位36.4个月,BCRFS2中位24.3个月。

核心结论

  • SSRT对前列腺床肉眼复发患者可获得显著生化控制,尽管存在不良特征仍允许延迟ADT。

研究设计与样本

  • 多中心回顾性系列,纳入三个意大利中心的连续患者,共90例接受SSRT,总剂量30-40 Gy/5次,平均SSRT前PSA 2.3 ng/mL。

主要发现

  • 平均随访21.2个月(范围2-64),17例(19%)同期接受ADT。
  • 完全生化反应(PSA nadir<0.2 ng/mL)39/90例(43.3%)。
  • BCRFS1(PSA较SSRT前升高>10%)25例(27.8%),中位BCRFS1时间36.4个月。
  • BCRFS2(PSA nadir<0.2 ng/mL者升高>0.2 ng/mL,或nadir<0.2 ng/mL者连续两次较nadir升高>25%)32例(35.5%),中位BCRFS2时间24.3个月。
  • 无>2级毒性。

临床怎么用

  • 对于未接受过放疗的前列腺床肉眼复发患者,可考虑SSRT以获生化控制并延迟ADT。

局限性

  • 回顾性设计,样本量90例,随访时间较短(平均21.2个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the safety and effectiveness of stereotactic salvage radiotherapy (SSRT) in RT-naïve patients affected by macroscopic prostate bed recurrence. PATIENTS AND METHODS: Consecutive patients treated for prostate bed macroscopic recurrence in three different Italian institutes were reviewed. Patients were treated with SSRT, with a total dose of 30-40 Gy in five fractions, the mean pre-SSRT PSA level was 2.3 ng/mL. Two different PSA thresholds were defined and biochemical recurrence-free survival (BCRFS) was reported, in order to better express outcome: BCRFS1 (a PSA level increase of >10% compared to the pre-SSRT value) and BCRFS2 (a PSA level increase of >0.2 ng/mL for patients with a PSA nadir of <0.2 ng/mL or two consecutive PSA level increases of >25% compared to nadir in patients with a PSA nadir of <0.2 ng/mL). RESULTS: In all, 90 patients were treated, with a mean (range) follow-up of 21.2 (2-64) months, and 17 of these patients (19%) had concomitant androgen-deprivation therapy (ADT) during SSRT. Complete biochemical response, defined as a PSA nadir of <0.2 ng/mL, was obtained in 39 of the 90 patients (43.3%). Considering BCRFS1, 25 patients (27.8%) had BCR, with an actuarial median BCRFS1 time of 36.4 months. For BCRFS2, BCR was reported in 32 patients (35.5%), with an actuarial median BCRFS2 time of 24.3 months. There was no Grade >2 toxicity. CONCLUSIONS: SSRT was found to yield significant biochemical control and allowed ADT delay despite adverse features.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Francolini G, Jereczek-Fossa BA, Di Cataldo V, et al. Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. BJU Int. 2019. PMID: 31608534. doi:10.1111/bju.14924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。